AstraZeneca-supported researcher and director of Jilin Cancer Hospital, Cheng Ying, passes away suddenly.
In a shocking turn of events, Dr. Cheng Ying, a top-tier cancer expert and the Director of Jilin Cancer Hospital, has passed away at the age of 62. The cause of her death remains undisclosed [1].
Dr. Cheng Ying was a beacon of hope in the medical community, particularly in the field of oncology. Her most recent publicly documented appearance was on May 10 at the annual meeting of the small-cell carcinoma committee of the Chinese Anti-Cancer Association in Changchun, where she served as chairwoman and presented a report on research into small-cell carcinoma [1]. Her last appearance at the specialist team clinic she led at the Jilin Cancer Hospital was on the morning of July 2, and her appointment schedule has since been removed from the hospital's outpatient information sheet [1].
Throughout her career, Dr. Cheng held various positions at Jilin Cancer Hospital, including director, deputy president, president, and party secretary. In 2009, she received the Chinese medical profession's highest honour, the Chinese Physician Award [2]. In 2014, she was named Outstanding Hospital President by the Chinese Hospital Association [2].
However, the connection between Dr. Cheng Ying's death and recent developments in cancer research remains unclear. A new oral treatment for blood cancer has been developed by Hong Kong researchers, offering a 97% cure rate [3]. It is not known if this new treatment is related to Dr. Cheng's work or death.
As of now, there has been no official statement regarding Dr. Cheng Ying's death. News about her from the past year has been removed from the Jilin Cancer Hospital's website [1].
[1] The Straits Times [2] China Daily [3] South China Morning Post
- Dr. Cheng Ying's contributions to the field of oncology, particularly her research into small-cell carcinoma, will continue to impact medical-conditions like cancer in the realm of health-and-wellness.
- Despite the recent development of a new oral treatment for blood cancer offering a high cure rate, the connection between this breakthrough and the late Dr. Cheng Ying's work or the cause of her death remains unexplored.
